



REVIEW ARTICLE

Cancer organoids: A platform in basic and translational research



Xin Ma ^{a,1}, Qin Wang ^{b,c,d,1}, Guozheng Li ^a, Hui Li ^a,
Shouping Xu ^{a,c,*}, Da Pang ^{a,b,c,*}

^a Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150081, China

^b Sino-Russian Medical Research Center, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150081, China

^c Heilongjiang Academy of Medical Sciences, Harbin, Heilongjiang 150086, China

^d Department of Pharmacology (The State-Province Key Laboratories of Biomedicine-Pharmaceutics of China), College of Pharmacy of Harbin Medical University, Harbin, Heilongjiang 150086, China

Received 14 May 2022; accepted 16 February 2023

Available online 12 April 2023

KEYWORDS

Drug assays;
Immunotherapy;
Mechanism research;
Organoids;
Precision medicine

Abstract An accumulation of previous work has established organoids as good preclinical models of human tumors, facilitating translation from basic research to clinical practice. They are changing the paradigm of preclinical cancer research because they can recapitulate the heterogeneity and pathophysiology of human cancers and more closely approximate the complex tissue environment and structure found in clinical tumors than *in vitro* cell lines and animal models. However, the potential applications of cancer organoids remain to be comprehensively summarized. In the review, we firstly describe what is currently known about cancer organoid culture and then discuss in depth the basic mechanisms, including tumorigenesis and tumor metastasis, and describe recent advances in patient-derived tumor organoids (PDOs) for drug screening and immunological studies. Finally, the present challenges faced by organoid technology in clinical practice and its prospects are discussed. This review highlights that organoids may offer a novel therapeutic strategy for cancer research.

© 2023 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co., Ltd. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

* Corresponding author. Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150040, China.
E-mail addresses: Shoupingxu@hrbmu.edu.cn (S. Xu), pangda@ems.hrbmu.edu.cn (D. Pang).

Peer review under responsibility of Chongqing Medical University.

¹ These authors contributed equally to this work.

Introduction

Cancer is a leading cause of global mortality with a huge impact on health, and social and economic development, necessitating progress toward preventive and treatment options. A total of 28.4 million cases are predicted by 2040 around the globe.¹ Therefore, the establishment of high-fidelity preclinical tumor models is crucial to investigate cancer-related mechanistic studies as well as allow personalized anti-cancer therapy in clinical.

Maintenance of tumor heterogeneity and mimicry of the microenvironment are challenges in establishing preclinical models. Cancer cell lines are limited in applications such as high-throughput drug screening due to the lack of tumor architecture and microenvironment.² Mouse models better mimic the *in vivo* situation but have low success rates, long generation cycles, high costs, and dubious clinical applications. Therefore, a three-dimensional (3D) cell culture technique producing "organoids" has been developed.³ Organoids are multicellular clusters with the *in vitro* capacity for self-renewal and proliferation while maintaining the physiological structure and function of the tissue from which they are derived.⁴ Compared with the traditional model, cancer organoids have their unique advantages, including a better ability to simulate the physiological and pathological state of tumor organs, moderate cost, and better combination with some emerging technologies. In addition, compared with traditional 2D cell culture, this 3D model maintains the mutation pattern without genetic changes during long-term culture, which makes it more suitable for studying dynamic processes, such as tumor development. These 3D constructs represent a promising, near-physiological model for human cancers, and exhibit enormous potential for translational studies of solid tumors.^{5,6} Thus, our review will discuss various cancer organoid culture strategies and summarize the recent advances in tumor organoids from the basic mechanism and clinical

application. Finally, the limitations of this emerging technology and future developments are discussed.

Establishment of organoids

Organoids are miniaturized *in vitro* organ models developed from stem cells or tumor tissues extracted from patients and grown in a specific 3D *in vitro* microenvironment. Organoids mimic the characteristics of real organs *in vivo* and 3D culture systems may be stably expanded.⁷ Tissue may be enzymatically and/or mechanically digested and cultured on a basement membrane (BME) or at the air-liquid interface, using Transwell inserts.^{8–10} Organoids may be passaged every 1–2 weeks. Crucially, the media in which organoids are cultured varies, often depending on the tissue of origin. For example, small intestinal organoids cultured with epidermal growth factor (EGF), R-spondin, and noggin, while colonic organoids require nicotinamide, the p38 inhibitor SB202190, prostaglandin E2, and the TGF- β inhibitor A83-014.⁸

Cancer organoids (Fig. 1) may be generated through differentiation of iPSCs or directly derived from tumor tissues,^{5,11} such as patient surgical specimens or needle biopsies.¹² Gao et al established metastatic prostate cancer 3D organoid cultures from patient biopsies and circulating tumor cells (CTCs).¹³ Cancer organoids derived from primary and/or metastatic samples of breast,^{14,15} bladder,¹⁶ colons,^{17,18} esophagus,¹⁹ stomachs,²⁰ gallbladders,^{21,22} head and neck,^{23–25} kidney,^{26,27} liver,^{28,29} lung,^{30,31} ovary,^{32,33} pancreas,^{34,35} and prostate^{13,36} cancers have been described (Table 1). Cancer organoids vary in their growth rate and size.¹² This depends on the culture system but is also influenced by the viability and amount of necrosis of the original tumor tissue, whether samples were taken pre- or posttreatment, and the sample processing time and technique. As with other organoids, PDOs retain many histological, transcriptional, and genetic




Figure 1 Schematic representation of patient-derived tumor organoids. Patient-derived tumor organoids from surgically resected/biopsied tissues and circulating tumor cells. Non-tumor organoids may be mutated into tumor organoids after gene editing.

Table 1 Culture systems of different cancer organoid models.

Tumoroid type	Extracellular matrix	culture components			Rf.
		Growth factors	Small Molecules	Molecule inhibitors	
Breast cancer	Basement membrane extract	Advanced DMEM/F12 Wnt3A EGF FGF-7/FGF-10 Noggin R-spondin 1	nicotinamide N-acetylcysteine B27 primocine neuregulin 1	A83-01 SB202190 Y-27632	14,15
Bladder cancer	Matrigel or Basement membrane extract	Advanced DMEM/F12 FGF-7/FGF-10/FGF-2	nicotinamide N-acetylcysteine B27	A83-01 Y-27632	16
Colorectal cancer	Matrigel	Advanced DMEM/F12 Wnt3A EGF FGF-10 Noggin R-spondin 1	nicotinamide PGE2 Gastrin N-acetylcysteine B27	A83-01 SB202190 Y-27632	17,18
Esophageal cancer	BME-2	Advanced DMEM/F12 Wnt3A EGF FGF-10 Noggin R-spondin 1	nicotinamide Gastrin N-acetylcysteine B27	A83-01 SB202190 Y-27632	19
Gastric cancer	Matrigel	Advanced DMEM/F12 Wnt3A EGF FGF-10 Noggin R-spondin 1	nicotinamide Gastrin N-acetylcysteine B27	A83-01 Y-27632	20
Gallbladder cancer	Matrigel	Advanced DMEM/F12 EGF FGF-10 IGF HGF Noggin	nicotinamide Gastrin N-acetylcysteine B27 Forskolin N2 Dexamethasone Primocin	A83-01 Y-27632	21,22
Glioblastoma	Matrigel	DMEM/F12 EGF/bEGF Noggin R-spondin 1	nicotinamide PGE2	CHIR99021 A83-01 SB202190 Y-27632	23,24
Head and neck squamous cell carcinoma	Matrigel	Advanced DMEM/F12 EGF FGF-10/FGF-2 Noggin R-spondin 1	N-acetylcysteine B27 Forskolin	CHIR99021 A83-01	25
Kidney cancer	Growth factor-reduced Matrigel or Basement membrane extract	Advanced DMEM/F12 EGF FGF-10 R-spondin 1	N-acetylcysteine B27 Primocin	A83-01 Y-27632	26,27
Liver cancer	Matrigel or Basement membrane extract	Advanced DMEM/F12 Wnt3A EGF, HGF FGF-10 Noggin R-spondin 1	nicotinamide Gastrin N-acetylcysteine B27 Forskolin	A83-01 Y-27632	28,29
Lung cancer	Matrigel	R-spondin 1 MBM Wnt3A EGF FGF-4/FGF-7/FGF-10 Noggin R-spondin 1	Dexamethasone /	A83-01	30,31
Ovarian cancer	Matrigel	Advanced DMEM/F12 EGF FGF-10 Noggin	nicotinamide N-acetylcysteine B27 forskolin primocine	A83-01 Y-27632	32,33

Pancreatic cancer	Matrigel	R-spondin 1	Heregulin β -1		34,35
		BMP-4			
		Advanced DMEM/F12	nicotinamide	A83-01	
		Wnt3A	PGE2	Y-27632	
		EGF	Gastrin		
Prostate cancer	Matrigel	FGF-10	N-acetylcysteine		13,36
		Noggin	B27		
		R-spondin 1	nicotinamide	A83-01	
		Advanced DMEM/F12	PGE2	SB202190	
		EGF,HGF	N-acetylcysteine	Y-27632	
		FGF-2/FGF-10	B27		
		Noggin	Dihydrotestosterone		
		R-spondin 1			

A83–01: Transforming growth factor-beta inhibitor which suppresses organoid proliferation; BME-2: Soluble basement membrane purified from Engelbreth-Holm-Swarm (EHS) tumor; contains laminin, collagen IV, entactin, and heparin sulphate proteoglycan; EGF: Binds EGF receptor to induce cancer cell proliferation; FGFs: A group of pluripotent and promiscuous growth factors; Gastrin: Stimulates proliferation and suppresses apoptosis of cancer cells; HGF: HGF/Met signaling promotes oncogenesis, tumor angiogenesis, and invasion; Nicotinamide: Vitamin B3 required for the long-term culture of organoids; Noggin: Inhibits bone morphogenetic proteins and modulates cellular differentiation, proliferation, and apoptosis; promotes bone metastasis of some cancers and is associated with tumorigenesis of primary bone malignancies; PGE2: Promotes angiogenesis in gastric cancer through up-regulation of vascular endothelial growth factor; R-spondin 1: Binds Lgr5 and a niche factor required for self-renewal of stem cells and activates Wnt signaling; facilitates growth and metastasis of cancer cells; SB202190: p38 inhibitor which suppresses the proliferation and migration of cancer cells; Wnt: Master regulator of cell development, proliferation, differentiation, adhesion, and polarity; aberrant Wnt signaling promotes carcinogenesis and cancer progression; Y-27632: Rho kinase inhibitor that reduces anoikis of dissociated stem cells, improves culture media, and promotes proliferation of tumor epithelial cells.

characteristics of the original tumor, maintaining the high heterogeneity of tumor cells in a simple and time-efficient culture system.^{37,38} However, culture stability may vary depending on tumor type and culture conditions. Therefore, characterizing and tracking the genotype and phenotype of organoids over time is essential to avoid culturing only one or a few dominant clones from heterogeneous tumor tissue and to ensure that the model represents the original tumor.

Applications of organoids in various cancers

Organoids are suitable preclinical models due to their ability to recapitulate the genotype, phenotype, and cellular features of their parent tissues. Some applications of patient-isolated organoids are listed in Figure 2.

Breast cancer

Dekkers et al described a protocol for long-term culture of normal human breast and breast cancer organoids from clinical samples¹⁵ and a diverse biobank of normal and breast cancer PDOs with a focus on triple-negative breast cancer (TNBC) has been compiled.³⁹ In addition, organoids have been used to study rare cancers, such as adeno-myoeplithelioma,⁴⁰ papillary carcinomas,⁴¹ Paget's disease,⁴² and TNBC with malignant pleural effusion,⁴³ and genes mimicking neoplasia have been knocked out by CRISPR/Cas9 in organoids for transplant into mice.⁴⁴ Furthermore, patient-specific drug sensitivity may be evaluated *in vitro* organoids to guide treatment.^{45,46} Other

applications include the identification of agents that reverse the epithelial–mesenchymal transition⁴⁷ and response to oncolytic agents for testing of oncolytic viruses.⁴⁸

Bladder cancer

The heterogeneity of bladder cancer causes a high mutation rate, high risk of recurrence, and poor prognosis. Culture systems for bladder cancer organoids have been mentioned in many studies.^{16,49,50} Mullonders et al created a live biobank of bladder cancer organoids from 53 patients in which common bladder cancer mutations were identified.¹⁶ In addition, Kong's team used organoid models to identify biomarkers that accurately predict responses to chemotherapy in 77 bladder cancer patients.⁵¹ Yu et al used organoids to assess chimeric antigen receptor (CAR) T cell-mediated cytotoxicity against bladder cancer.⁵²

Colorectal cancer

Several groups have successfully established organoids for colorectal cancer (CRC).^{53–68} For example, Zhao et al used organoid models to show that cancer stem cells (CSCs) and differentiated cancer cells (non-CSCs) have different metabolic phenotypes. Lactate derived from non-CSCs promoted self-renewal of CSCs, thereby promoting CRC progression.⁵⁵ Another study modeled the progression of colorectal tumors and metastases using paired PDOs and found that organoids from metastatic sites exhibited more tumorigenic and metastatic abilities than those from




Figure 2 Current applications of various cancer organoid models (references in brackets).

primary lesions.⁵⁴ Organoids have also been used to find more targeted therapies for CRC. Bruun et al developed an *in vitro* pharmacogenomic profiling platform using PDOs and found it useful for drug screening to find new therapeutic strategies for metastatic colorectal cancer.⁵⁹ Furthermore, the use of locally advanced rectal cancer organoids has demonstrated a strong matching of response to chemoradiotherapy between patients and organoids with an accuracy of 84.43%, a sensitivity of 78.01%, and a specificity of 91.97%.⁶⁴

Gastric cancer

Several studies have described procedures for creating gastric cancer organoids from clinical samples and have been successfully used for mechanistic studies of drug resistance.^{69–74} Ukai et al⁶⁹ established 5-FU-resistant gastric cancer organoids and Harada et al⁷⁰ established oxaliplatin-resistant gastric cancer organoids to explore the mechanism of gastric cancer resistance. In addition, several groups have developed organoid models of *H. pylori* infection for mechanistic studies of *H. pylori*-induced gastric cancer.⁷⁵ Organoids have also been used to study the more uncommon gastric cancers, such as Signet ring cell carcinoma.⁷⁶

Liver cancer

Broutier et al first established primary liver cancer organoids from eight surgically resected hepatocellular carcinoma (HCC), cholangiocarcinoma (CC), and combined HCC-CC subtypes in 2017.²⁹ Resistance to chemotherapy is common in all types of cancer while organoids of liver cancer have been shown to help identify mechanisms of resistance to anticancer drugs.⁷⁷ Furthermore, Liu et al established 3D co-culture models of primary liver tumor-derived organoids with CAF to understand their interaction and response to chemotherapeutic agents.⁷⁸

Lung cancer

Biobanks of lung cancer organoids and normal bronchial organoids have been established from primary lung cancer tissues, including adenocarcinoma,^{79–82} squamous cell carcinoma,³⁰ small cell carcinoma,⁸³ large cell carcinoma,³¹ and adenosquamous carcinoma,³⁰ as well as paired non-neoplastic airway tissues.⁸⁴ In addition, Dijkstra et al found a 17% rate of pure non-small cell lung cancer (NSCLC) organoid formation by assessing samples from >70 NSCLC samples, indicating that the methods of establishing pure NSCLC organoids from intrapulmonary lesions require improvement.⁸⁵ Lung cancer organoid models can also accurately select anticancer drugs based on drug sensitivity to provide a powerful supplement and validation for gene sequencing.^{86,87}

Ovarian cancer

Kopper et al established 56 organoids from 32 patients representing all major subtypes of ovarian cancer, including serous borderline tumor (BT), mucinous BT, low-grade serous BT, mucinous carcinoma, endometrioid carcinoma,

clear cell carcinoma, and high-grade serous subtype.³² In addition, high-grade serous ovarian cancer organoids require a low Wnt environment for long-term growth.^{88,89} Some studies have shown that PDOs are physiologically appropriate *in vitro* tumor drug screening models and can use effective personalized drugs to target ovarian cancer.^{90–94} De Witte et al assessed the ability of PDOs to predict functional consequences of clinical drug response and tumor heterogeneity and showed that PDO drug screening identified 88% of patients as highly responsive to at least one drug.⁹²

Pancreatic cancer

Pancreatic cancer is characterized by elevated intra-tumoral and intertumoral heterogeneity and a highly malignant phenotype which makes it difficult to establish organoids. Pancreatic ductal organoids are an *in vitro* model of pancreatic ductal adenocarcinoma (PDAC) and can be investigated in patients with local, advanced, and malignant metastases by surgical, fine needle aspiration of ascites specimens.^{95–103} Furthermore, Huang et al¹⁰⁴ and Beato et al¹⁰⁵ established the intraductal papillary mucinous neoplasms (IPMNs) organoid biobank to investigate the genetic and biological mechanisms of IPMNs. Another study achieved rapid molecular profiling and drug detection by generating PDOs from free DNA which has implications for clinical practice.¹⁰⁶ Briefly, PDOs can mimic the response of primary tumors to drug therapy and therefore have the potential for translational research and drug discovery.

Prostate cancer

Human prostate cancer organoids have also been created. Karkampouna et al developed prostate cancer models with specific biological and genetic landscapes that can be used to investigate tumor growth, metastasis, and drug resistance in the early stages of the disease and to assess response to chemotherapy.³⁶ Servant et al developed a biobank that included prostate cancer organoids from 81 patients for the construction of stable cell lines.¹⁰⁷ In addition, the use of other biotechnologies in combination with prostate cancer organoids has helped to better investigate the complexity of tumor pathogenesis as well as integrate the tumor microenvironment.^{108,109}

Other cancer

In addition to the organoids described in detail above, other organoids have also developed well in recent years. For example, some studies have shown that specific, targeted therapy for individual patients can be guided by PDO produced in biopsies from patients with esophageal cancer, including esophageal adenocarcinoma and esophageal squamous cell carcinoma.^{110–112} The head and neck squamous cell carcinoma (HNSCC) organoids established by Driehuis et al have been used to assess the efficacy of targeted photodynamic therapy for HNSCC.¹¹³ Many methods for generating patient-derived glioblastoma organoids have been established.^{114–117} Patient-derived glioblastoma organoids have been demonstrated to




Figure 3 Application of organoids in cancer research. Organoid technology combined with CRISPR/Cas9 gene editing allows the impact of genetic changes on disease development to be studied. Organoid biobanks can be used for drug screening and validation. Patient-derived tumor organoids co-culture with immune cells mimics the mechanism of immunotherapy efficiency and drug resistance. In addition, tumor organoid models may become a tool for personalized medicine validation to optimize treatment selection.

recapitulate key features of the tissue of origin, including their histological features, cellular diversity, gene expression patterns, and mutation profiles.²⁴

In brief, organoids have been applied (Fig. 3) to disease model construction, tumor mechanisms, drug screening, testing cancer immunotherapy, and developing new methods for personalized medicine.

Tumor mechanisms

Tumorigenesis

Tumorigenesis is characterized by multistep genetic alterations that lead to the inactivation of tumor suppressor genes and activation of oncogenes which together drive cancer growth.^{118,119} Introduction of targeted mutations by CRISPR-Cas9 allows tumorigenesis to be mimicked.¹²⁰ Colorectal cancer (CRC) may be mimicked by the CRISPR-Cas9 introduced mutations of KRAS, Apc, p53, and Smad4.^{121,122} Organoids with activating mutations in KRAS (KRAS^{G12D}) and inactivating mutations in Apc, TP53, and Smad4 grow independently of the stem cell growth factors, EGF, WNT, R-spondin1, and noggin. Primary colonic organoids may be transformed into adenocarcinoid tumors via mutation of Apc, p53, Kras^{G12D}, and Smad4, and gastric and pancreatic organoids transformed by p53 loss, Kras^{G12D} expression, or both.¹⁰ Naruse et al used four genotoxic chemicals, ethylmethanesulfonate (EMS), acrylamide (AA), diethylnitrosamine (DEN), and 7,12-dimethylbenz [a] anthracene (DMBA) to study chemical carcinogenesis.¹²³ DMBA-treated mammary tissue-derived organoids with a heterozygous knockout of Trp53 showed tumorigenicity

while organoids with wild-type Trp53 did not, consistent with previous reports on corresponding mouse models. Pulmonary organoids with or without Trp53 knockout developed oncogenic histopathological features with oncogenic kinase activity in subcutaneous nodules when treated with EMS or AA and similar changes were found in hepatic organoids treated with DEN. Tumor organoid technology has also been used to investigate pathways involved during tumorigenesis. Mouse colonic organoids have been used to demonstrate that aryl hydrocarbon receptor (AhR) signaling regulates the IL22 response by regulating SOCS3 expression, validating a rationale for using AhR to reduce colon cancer risk.¹²⁴ lnc-RP11-536 K7.3 was shown to promote colon cancer (CC) progression in CC-derived organoids through the SOX2/USP7/HIF-1 α signaling axis, revealing regulation of chemosensitivity and exposing therapeutic targets related to lncRNAs.⁶³ All these results demonstrate the utility of gene-editing organoid systems in validating driver pathway mutations in tumorigenesis, thus providing a flexible *in vitro* cancer model for the study of tumorigenesis.

Although CRISPR-Cas9 has been successfully used in organoids, precise integration of exogenous DNA sequences into organoids is lacking robust knock-in approaches. CRISPR-Cas9-mediated homology-independent organoid transgenesis (CRISPR-HOT) enables knock-in human organoids representing different tissues to be generated.¹²⁵ CRISPR-HOT simplifies gene editing and has been used to introduce fluorescent labeling of reporter gene products for subcellular visualization in intestinal cells. Moreover, CRISPR-HOT has been used to generate human liver ductal organoids and human fetal hepatocyte organoids within 2–3 months.¹²⁶ The application of CRISPR-HOT to organoid

Table 2 Cancer organoid biobanks.

Tumor type	Source		Success rate (%)	Achievement	Rf.
	Type	Quantity			
Breast cancer	Ductal adenocarcinoma, lobular adenocarcinoma	100 patients	>80	Used for cancer research, drug development, and to assess personalized <i>in vitro</i> drug responses. New protocol for obtaining patient-derived organoids from breast cancer	14
	invasive ductal carcinoma, invasive lobular carcinoma	33 patients	87.5		197
Bladder Cancer	Urothelial carcinoma	16 patients	70	<i>In vitro</i> model of tumor evolution and therapeutic response to precision cancer medicine. Bladder organoids biobank for drug testing in the future.	198
	Squamous-cell carcinoma	50 patients	50		16
Colorectal cancer	Primary tumor	20 patients	90	Tumor organoids may fill the gap between cancer genetics and patient trials for drug research as well as personalized therapy. Functional links between genetic alterations, niche requirements and biological phenotypes of tumors, providing a multifunctional platform for biomedical research. Personalized screening tool using patient-derived tumor organoids. Platform to analyze cancer cell heterogeneity, assess personalized drug treatment response and treatment resistance.	17
	Primary tumor	43 patients	100		18
	Metastases	14 patients	71		37
Esophageal cancer	Oesophageal squamous-cell carcinoma, Oropharyngeal squamous-cell carcinoma	21 patients	71.4	Identified potential targeted drugs to guide patient drug selection.	110
Gastric cancer	Normal, dysplastic, cancer, and lymph node metastases	34 patients	>50 (tumor)/>90 (normal)		199
Glioblastoma	IDH1 mutant tumors, recurrent tumors	53 patients	91.4	The establishment a large cohort of unique organoids and patient-derived orthotopic xenografts of various glioma subtypes. The establishment a large cohort of unique organoids and patient-derived orthotopic xenografts of various glioma subtypes	24
	IDH1 mutant IV glioblastoma (GBM), IDH1 mutant II-III gliomas	173 patients	79/68		117
Head and neck squamous cell carcinoma	Primary tumor	40 patients	65	Comparison of organoids with normal epithelium applied to <i>in vitro</i> drug screening.	25
Kidney cancer	Wilms tumors, malignant rhabdoid tumors (MRTK), renal cell carcinomas (RCC), and congenital mesoblastic nephromas	50 children	100(normal)/75 (Wilms tumors)/100(MRTK)/75(RCC)	Captures heterogeneity of pediatric renal tumors; well-characterized model for basic cancer research, drug screening and personalized medicine.	27
Lung cancer	Non-small cell lung cancer	14 patients	71.43	A living biobank of patient-derived organoids from non-small cell lung cancer patients was established. Successfully construct biobank of lung cancer organoids	200
	adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma, large cell carcinoma, and small cell carcinoma	36 patients	87		30

(continued on next page)

Table 2 (continued)

Tumor type	Source		Success rate (%)	Achievement	Rf.
	Type	Quantity			
Liver cancer	Hepatocellular carcinoma	10 patients	26	Hepatocellular carcinoma (HCC) organoids generated from needle biopsies of patients with liver cancer; response to sorafenib treatment.	201
ovarian cancer	Borderline tumors, Clear-cell carcinoma, Endometrioid carcinoma, Mucinous carcinoma, Serous carcinoma	32 patients	65	Ovarian cancer organoids can be used for drug-screening assays and different tumor subtype responses to platinum-based chemotherapy.	32
Pancreatic cancer	Ductal adenocarcinoma (primary tumor and Metastases)	138 patients	75	Predict drug responses in pancreatic cancer patients and provide a rational for prioritizing therapeutic regimens.	202
	pancreatic ductal adenocarcinoma (PDAC)	39 patients	/	Revealed functional heterogeneity in Wnt niche independence in PDAC.	203
	Intraductal papillary mucinous neoplasms (IPMNs)	8 patients	/	Potential drivers of IPMN tumor development were identified.	104
	Intraductal papillary mucinous neoplasms (IPMNs)	15 patients	81(tumor)/87(normal)	The mechanism of IPMN invasion was revealed.	105
Prostate Cancer	Adenocarcinoma metastases Circulating tumor cells	7 patients	15–20	Recapitulated the molecular diversity of prostate cancer subtypes, providing an <i>in vitro</i> model for understanding disease pathogenesis and response to therapy.	13
Neuroendocrine tumors	Gastroenteropancreatic (GEP) neuroendocrine neoplasm (NEN)	39 patients	/	Understanding of GEP-NEN and its genetic and biological phenotypes.	204

construction allows universal reproduction of the process of tumorigenesis.

Tumor metastasis

Cancer metastasis involves the spread of cancer cells from the primary site to other organs and is the leading cause of death in cancer patients.¹²⁷ Metastasis is a complex molecular process and maintenance of tumor pathophysiological features by organoids renders this a suitable platform for study. For example, Fujii et al generated four independently matched sets of organoids for primary colorectal cancer and metastatic lesions. Exome sequencing confirmed that they share similar genetic profiles and niche factor requirements and metastasis-derived organoids exhibit higher metastatic capacity.¹⁸ Cancer organoids can also help identify critical targets that inhibit tumor metastasis. SOX4 has been shown to promote the maintenance of an undifferentiated and proliferative state in breast cancer organoids. Compared to SOX4-positive breast cancer organoids, SOX4-knockdown breast cancer organoids contained more differentiated cells, had intraluminal or basal gene expression patterns and lower levels of cell cycle genes, and showed the impaired ability of tumor metastasis and growth.¹²⁸ Another study revealed that SOX2 was identified as having pro-metastatic activity from primary tumor-derived organoids matched with liver

metastases of CRC patients. Thus, SOX2 is thought to be associated with CRC invasion and proliferation as well as liver metastasis.⁵⁴ In addition, organoids were generated from primary and metastatic breast cancer tissues and accurately replicated histopathology, hormone receptor status, HER2 status, and DNA copy number changes in a previous study conducted by Sachs N et al.¹⁴ This suggests that organoids can accurately mimic native as well as metastatic tumors and provide a better understanding of cancer biology. In short, cancer organoids provide an effective tumor model to investigate the mechanisms of promotion and inhibition of tumor invasion.

Drug assays

Most cytotoxic agents are more effective in tumor cell lines than in patients, in whom tumor responsiveness varies greatly according to tumor type.¹²⁹ Voskoglou-Nomikos et al established that cell line *in vitro* models predict cytotoxic responses of non-small cell lung cancer but not of colon cancer under a disease-oriented approach.¹³⁰ Organoids are closer to physiological structures and more realistically reproduce drug responses filling a gap between drug screening and clinical trials. Several tumor organoid biobanks (Table 2) have been established for the identification and testing of new drugs and toxicology assessments.^{14,16,18,30,32}

Drug efficacy testing

As an *in vitro* individualized preclinical model, organoids have great potential in susceptibility testing of individualized drugs. Organoids from metastatic gastrointestinal cancer (colorectal and gastroesophageal) have been tested for their ability to predict a patient's treatment response. It accurately reproduced the patient treatment response of gastrointestinal cancer with high sensitivity (100%), specificity (93%), positive predictive value (88%), and negative predictive value (100%).¹³¹ Li et al used signet ring cell carcinoma (SRCC) and non-SRCC organoids to observe treatment responses to 5-fluorouracil, oxaliplatin, docetaxel, and irinotecan. The SRCC organoid system had a lower IC₅₀ value for docetaxel than the non-SRCC. No further differences were found between the two types of organoids for other drugs.⁷⁶ The sensitivity of 40 drugs and gene expression profiles of 38 CRC liver metastases from 22 patients were tested using PDOs. Sensitivity to several anticancer drugs and antimetabolites that have not previously been used to treat CRC was revealed while some drugs without clear genomic markers (alisetidine b and navitoclax) showed heterogeneity in anticancer activity.⁵⁹ In addition, cancer organoids are also effective tools to interrogate gene–drug associations. A study showed that TP53 mutant organoids were insensitive to nutlin-3a in the biliary tract and CRC organoids.¹³² This result is consistent with clinical findings in cancer patients with TP53 mutations. Cancer organoids have also facilitated research into mechanisms of therapeutic resistance.^{30,70,133,134} Among oxaliplatin-resistant GCOs, the presence of myoferlin was shown to be strongly associated with the acquisition of oxaliplatin resistance.⁷⁰ In another study, expression of atypical cyclin P was found to promote the stem-like phenotype of intestinal cancer organoids, which often leads to tumor recurrence, metastasis, and treatment resistance.¹³⁴

Personalized treatment options have been explored via organoid predictions. Combination therapy with RAS pathway inhibitors and drugs (HER2 inhibitor selafatinib, MEK inhibitor selumetinib, and ERK inhibitor SCH772984) in CRC organoids with wild-type or mutant RAS were evaluated and further oncogenic mutations were introduced by CRISPR. The combination of afatinib with selumetinib and SCH772984 with selumetinib both inhibited mutant organoid growths, demonstrating the potential of patient-derived CRC organoid repertoires for preclinical assessment of inhibitors and drug combinations.¹³⁵ A blinded study cultured 77 samples from 57 patients with stage IV colorectal cancer to generate organoids and evaluate the predictive accuracy of chemotherapy responses. Organoids and metastatic tissues were very consistent with the original cancer tissues, preserving histological features and marker expression. The sensitivity, specificity, and precision of patient-derived tumor organoid models for chemotherapy response prediction were 63.33%, 94.12%, and 79.69%, respectively.¹³⁶ These studies have shown that for patients, organoid sensitivity testing technology can quickly detect the most appropriate drugs, develop the best and most effective drug treatment regimen, and reduce the probability of drug side effects, drug resistance, and tumor recurrence, so as to obtain the best treatment.

Cancer organoid biobanks can serve as critical models for new drug discovery. This may shorten the preclinical trial cycle, reduce development costs and risks, improve the success rate, and facilitate drug discovery. Plocabulin is a novel microtubule-disrupting antitumor agent of marine origin currently undergoing phase II clinical trials. Costales-Carrera et al used 3D tumor organoids from 3 CRC patients to show that plocabulin is strongly cytotoxic to CRC.¹³⁷ Organoids represent a reproducible platform for personalized drug screening which addresses inter- and intra-tumoral heterogeneity despite the small sample sizes of most studies to date although there is more work to be done before they are a predictive tool for clinical decision-making.

Drug toxicity testing

Tissue-derived organoids allow the selection of drugs that specifically target cancer cells but do not damage healthy cells. At present, general cell screening and animal model screening often fail to accurately predict adverse reactions in humans. The organoid model plays a vital role in drug toxicity screening. Indeed, hepatotoxicity, cardiotoxicity, and nephrotoxicity are the main causes of drug clinical trial failure. Liver organoids have been used to assess hepatotoxicity.^{138–140} For example, Mekky et al used human liver organoids to test the toxicity of aspartic acid-coated magnesium oxide nanoparticles and valproate showing that these drugs decrease cell viability, decrease ATP, and increase reactive oxygen species in hepatocytes.¹³⁹ Similarly, cardiac organoids were used to demonstrate that hypoxic cardiac injury aggravates the cardiotoxicity of doxorubicin.¹⁴¹ Cardiac organoids from mouse embryonic stem cell-derived embryoid bodies¹⁴² and human iPSCs have also been used for drug testing,¹⁴³ as have iPSC-derived kidney organoids for nephrotoxicity screening.¹⁴⁴ These organoids provide patient-specific models for investigating the toxicity of anticancer drugs in personalized medicine.

Immunological studies

Immunotherapy involves tumor recognition by the immune system and initiation or enhancement of immune responses. Non-specific immunotherapy introduces adjuvants, such as cytokines or other cell signaling molecules, to enhance overall immune activity while specific immunotherapy induces antigen-specific immune responses to one or more tumor targets. Anti-cancer vaccines, dendritic cell therapy, or oncolytic viruses may be used. T-cell and antibody-based therapies administer immune system components to act directly on the tumor or enhance existing immunity.^{145–147} However, most patients are insensitive to immunotherapy due to poor tumor immunogenicity and immune escape mediated by the tumor microenvironment.¹⁴⁸ Immunotherapy cannot simulate the complex tumor microenvironment of pericytes and fibroblasts, resident or infiltrating vascular structures (endothelial cells), and immune cells because cancer cell lines do not reproduce the heterogeneity of tumor epithelial cells and the mouse immune system is too different from the human. However, cancer organoids preserve the characteristics of

the human immune system and are gradually becoming a powerful tool for studying cancer immunotherapy.

Two conceptually different approaches have been described to construct the tumor microenvironment. (i) In reconstitution models, cancer organoids are cultured in an extracellular matrix, such as Matrigel or BME-2, and immersed in a tissue culture medium; exogenous immune cells, from autologous peripheral blood or tumors, are co-cultured with the organoids.^{50,61,72,78,97,149} (ii) In the overall native organoid model, the innate immune microenvironment (endogenous immune cells and other non-epithelial cell types) of tumor specimens is preserved without reconstitution. Organotypic tumor spheroids (40–100 μ m) have been cultured in a microfluidic device containing collagen for 5–9 days, preserving tumor cells and endogenous immune cells, such as lymphocytes and medullary cell populations.¹⁵⁰ Alternatively, primary tissue fragments containing tumor cells and immune components were embedded in collagen gels within Transwell dishes for air-liquid interface (ALI) culture. The top of the collagen gel is exposed to air, allowing the cells to obtain an adequate supply of oxygen. Many different primary tumors, including colon, lung, pancreas, and kidney have been cultured for up to 30 days. The complex histological tumor microenvironment is preserved with tumor parenchyma and stroma, including functional and tumor-infiltrating lymphocytes (TILs).^{151,152}

The lack of functional blood vessels may lead to immature organoids, necrotic kernels, and premature differentiation, and vascularization would support the growth of more viable organoids. Organoid angiogenesis may be achieved by implanting organoids into highly vascular animal tissues, such as chicken chorion allantois membrane, where host blood vessels penetrate the organoid.¹⁵³ Mesodermal precursor cells have been incorporated into human tumors and neural organoids, thereby forming vascularized organoids *in vitro*.¹⁵³ Vessels may add layer-by-layer deposition to *in vitro* co-cultures or form tubular voids by selective removal of material that is seeded with endothelial cells and connected to the perfusion network.¹⁵⁴ Alternatively, vascular endothelial growth factor (VEGF) and hypoxia gradients within a compartmentalized microfluidic chip have been used to induce vascularization in organoid-endothelial cell co-culture.¹⁵⁵

Tumor immunobiology

Bone marrow and thymus are the sites of development, differentiation, and maturation of immune cells and aid the development of peripheral immune organs. Stromal cells form a scaffold for thymic tissue that promotes differentiation and proliferation of thymic epithelial cells (TECs) to support thymic function and T lymphocyte maturation.^{156,157} 3D thymic organoids may be generated by thymocytes isolated from NOD SCID mice or postpartum tissue which are dissociated with deoxyguanosine and cultured on gel foam sponges during the process of reaggregation fetal thymic organ culture (FTOC). Thymocyte aggregates are cultured with hematopoietic stem cells (HSCs) to support the development of T cells after transplantation into athymic mice.^{158–160} However, to avoid T cell dysplasia due to different sizes of tissue samples, isolated tissues have

been cultured in a single suspension and on gelatin foam at the air-liquid interface, in the process of reaggregation thymic organ culture (RTOC) which maintains the 3D conformation necessary for T cell function.¹⁶¹ An artificial thymic organoid system (ATO) has also been constructed by adding aggregates co-cultured from HSCs and MS5-hDLL1 cells (genetically modified allantois cell line expressing human DLL1 or DLL4) to cell culture inserts at the air-liquid interface in serum-free medium.¹⁶² The ATO system has been used to assist ESC and iPSC in the production of conventional T cells, providing a controllable, efficient, and stable tool for studying human thymus function.^{163,164}

The lymph node peripheral cortex is characterized by a spatially organized extracellular matrix (ECM) with lymphoid follicles, rich in B cells and follicular dendritic cells (FDCs).¹⁶⁵ Suematsu et al implanted thymus-derived stromal cell lines together with dendritic cells into biocompatible scaffolds, after which they were transplanted into the subcapsular space of mouse kidneys and generated a lymphoid tissue organoid which retains a secondary lymphoid organ structure and contains a network of compartmentalized B and T cell clusters, high endothelial venule-like vessels, germinal centers, and follicular dendritic cells. This simplified lymphoid tissue organoid assists with studies of secondary lymphoid organ development and induction of adaptive immune responses and may be used to interrogate tumor immune escape mechanisms.¹⁶⁶ Votanopoulos et al generated melanoma/lymph node organoids by introducing patient tissue into an ECM-based hydrogel system to create three-dimensional (3D) mixed immune-enhanced patient-derived tumor organoid (iPDO) after washing them with saline, antibiotics, and erythrolysis buffer. This mixed organoid preserves both tumor heterogeneity and stromal and immune cell components. The iPDO reflects immunotherapy responses in 85% of patients and activates patient-matched peripheral blood T cells for killing tumor cells in the naïve PDO.¹⁶⁷ Immune organoids allow the immune system and tumor cells of individual patients to remain viable and permit the mechanistic study of hematological malignancies. Using these organoids, mutations in mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) protease and caspase recruitment domain-containing protein 11 (CARD11) mutations were found to be involved in activated B-cell like diffuse large B-cell lymphoma, the molecular subtypes of which are activated through different genetic pathways.^{168,169}

Tumor immunotherapy

Immune checkpoint inhibitors (ICIs)

Targeting of PD1/PD-L1 and CTLA-4 by ICIs produces a clinical response among only some patients with melanoma,¹⁷⁰ skin squamous cell carcinoma,¹⁷¹ non-small cell lung cancer,¹⁷² renal cell carcinoma,¹⁷³ head and neck cancer,¹⁷⁴ and tumors with mismatch repair defects.¹⁷⁵ *In vitro* systems that preserve the tumor microenvironment (TME) may facilitate the development of more precise immuno-oncology. Kong et al co-cultured CRC organoids with autologous TILs to demonstrate the migratory and tumor cytotoxic activities of TILs, indicating the

maintenance of the immune checkpoint, the PD-1/PD-L1 pathway.¹⁷⁶ Courau and colleagues demonstrated that CRC organoids respond to immune infiltration by up-regulating HLA-E, a ligand for the CD8 and NK cell receptor, NKG2A, and that anti-MICA/B increases NKG2A while stimulating anti-tumor responses. Synergistic actions of anti-MICA/B and anti-NKG2A may be a potential immunomodulator in CRC patients.¹⁷⁷ Chakrabarti et al investigated the potential link between the human epidermal growth factor receptor 2 (HER2) and PD-1/PD-L1 in co-cultures of human gastric cancer organoids, cytotoxic T lymphocytes (CTLs), and myeloid-derived suppressor cells (MDSCs). Knockdown of HER2 decreased PD-L1 expression and increased CTL infiltration and an antitumor effect. Co-expression of HER2 and PD-L1 may contribute to tumor cell immune escape, indicating a potential treatment for patients with anti-PD-1/anti-PD-L1 resistance.⁷² However, it must be acknowledged that the addition of a single immune cell type may not completely reproduce the complex interactions between different immune cell populations.

Holistic culture systems, including microfluidic and ALI methods, can be used for the functional modeling of ICIs. 3D microfluidic culture can reproduce *in vivo* therapeutic sensitivity when organoids were generated from MC38 and GL261 tumors (sensitive to PD1), CT26 (moderately sensitive to PD1) or B16F10, human melanoma and Merkel cell carcinoma (resistant to PD-1). Moreover, a combination of anti-PD-1 and TBK1/IKK ϵ inhibitors helped to overcome immunosuppressive TME.¹⁵⁰ Deng et al identified the CDK4/6 inhibitor which increased T cell infiltration and had a synergistic action with that of anti-PD-1, thereby improving anti-tumor activity.¹⁷⁸ ALI culture of organoids with a blockade by anti-PD-1 or/and anti-PD-L1 resulted in expansion and activation of tumor antigen-specific T cells.¹⁷⁹ These examples show the potential of immune-tumor organoids in detecting antibody-mediated therapy, identifying novel therapeutic targets, and visualizing and enhancing immune cell migration and tumor infiltration.

Adoptive cell transfer-therapy

Adoptive cell transfer therapy (ACT) includes TILs, chimeric antigen receptor T cell therapy (CAR-T), and T cell receptor therapy (TCR).¹⁸⁰ CAR-T and TCR cell therapies involve extracting T cells from the patient's peripheral blood and genetically engineering them to express tumor-specific ligands. Cancer organoid models, particularly those containing TME components, are capable of monitoring and enhancing CAR cell recruitment and penetration in tumor tissue and subsequent killing. CAR NK-92 cells expressing EGFRvIII¹⁸¹ and CAR-T cells targeting bladder cancer-specific antigens⁵² have been analyzed using organoids. Glioblastoma organoids co-cultured with CAR-T cells have been a tool in immunotherapy research.¹¹⁵ These organoid immune cell co-culture systems can be used to assess car-mediated tumor-specific cytotoxicity in normal and tumor organoids. In addition, PDOs can be used as a source of tumor-reactive T cells, a culture platform to enrich them, and can induce and assess the killing efficiency of tumor-specific T cells. CAR-T cells expressing ligands for CD39 hepatitis B virus (HBV) surface protein and personalized tumor-reactive CD8 T had activity against hepatocellular carcinoma

organoids.¹⁸² Although this study is currently limited to low patient numbers it proves the concept of organoid models being suitable for immunotherapy development.

Oncolytic virus-therapy

Oncolytic viruses are replication-competent and tumor-targeted to infect and kill tumor cells while stimulating the host to produce an anti-tumor immune response.¹⁸³ Organoid models of pancreatic cancer,¹⁰² bladder cancer,¹⁸⁴ glioblastomas,¹⁸⁴ and breast cancer⁴⁸ have been used as a screening platform for oncolytic viral therapy. A renal cell carcinoma PDO (RCC PDO) was tested with an oncolytic adenovirus into which a cross-hybridized Fc-fusion peptide, consisting of Fc with IgA1 and IgG1 constant domains, attached to the PD-1 outer domain had been cloned. The fusion peptide bound to PD-L1 and activated IgA1 neutrophils and IgG1 natural killer and complement activation functions enhancing tumor killing relative to anti-PD-L1 (atezolizumab), IgG1-PDL1, and IgA-PDL1.¹⁸⁵ Although these studies suggest promise for PDOs in studying oncolytic virus infectivity and cytotoxicity, to our knowledge, immune responses triggered by oncolytic viruses have not been investigated in complex immune-organoids.

Immunotherapy research has driven the development of novel cancer therapies, either alone or in combination with other therapies, to target immunomodulatory pathways and advance the control of cancer cells. PDOs combine TME characteristics and mimic immunotherapy responses, while co-culture with immune cells mimics the mechanism of immunotherapy efficiency and drug resistance. Overall, cancer organoids can not only elucidate potential resistance pathways but may also contribute to therapeutic efforts, such as *in vitro* screening and optimization of drugs and cellular immunotherapies; if short-term responses in culture do accurately reflect clinical responses and long-term outcomes, they can also determine patient sensitivity to single or combination therapies in real time. In the future, organoid approaches will greatly facilitate the basic science and translation of immuno-oncology and accelerate the development of personalized immunotherapy for human tumors.

Current limitations and future opportunities

Many features of human cancer development and progression are reproduced by cancer organoids but the pathophysiology and clinical relevance could be improved. Firstly, although three-dimensional organoids constructed *in vitro* already have structures of some organs compared with intact organs *in vivo*, the structures are still relatively simple and can only partially reflect tissue characteristics. Additional supplements, such as IL-2, anti-CD3, and anti-CD28 antibodies, are often required to maintain immune cells in co-culture with organoids. The animal origins of the 3-D collagen-rich lamin, Matrigel, which is essential for organoid culture may also influence treatment outcomes. There is also variation in PDO generation due to a lack of standardized methodology plus ethical issues around the transplantation of organoids into humans, all of which must be addressed. Secondly, organoid culture varies according to the tumor type and starting material with treatment-directed tumor shrinkage affecting the success of the

culture. Similarly, metastasis-derived organoids are difficult to generate, especially with inter-organ spread, and must be validated using mouse xenograft models. Thirdly, tumor-derived organoids usually grow more slowly than healthy tissue-derived organoids which leads to the contamination of tumor organoids with healthy tissue.^{85,186} Non-solid tumors cannot be reproduced as organoids and more complex brain organoids are still a major challenge. Fourthly, PDOs establishment takes 4–6 weeks plus approximately 2–4 weeks to screen for anticancer drugs, reducing the chances of coinciding with the optimal therapeutic window for patients. Moreover, the production of PDOs is currently very expensive, and the technology is immature and difficult to incorporate into existing healthcare systems. The ethical significance of tumor organoid biobanking also requires further consideration. Despite these limitations, organoid cultures are a physiologically relevant model for translational applications and personalized cancer drug development.

Yin et al.¹⁸⁷ established an *in vitro* tumor model of a patient-derived tumor cell cluster by simultaneously optimizing the medium in Matrigel-free conditions. This model allows short-term cell expansions from primary tumors, including immune and fibroblast populations, allowing the investigation of hundreds of therapeutic options per patient in a manner that correlated with clinical performance. This model excludes the influence of extrinsic factors such as Matrigel on subsequent studies while allowing drug prediction within the patient's optimal therapeutic time window. However, the chronic culture of patient-derived tumor cell clusters leads to the loss of stromal cells and their drug response patterns may be altered.

At present, the "Organ-on-a-chip" technology formed by the integration of organ chip and organoid can address some problems very well. A typical example is the application of microfluidic devices in an *in vitro* tumor organoid model. The interaction between tumor and stroma was investigated mechanically by simulating the spatial organization of the tumor microenvironment on a chip. It has been observed that tumor-associated fibroblasts (CAF) enhance the expression of glycoprotein non-metastatic B in breast cancer cells, thereby promoting invasion.¹⁸⁸ The organoid-on-a-chip allows simulation of the microenvironment and establishment of interrelationships between tissues and multiple organs.¹⁸⁹ Lung cancer organoids combined with microfluidic chip technology have produced drug responses within a week.¹⁹⁰ In addition, Shirure et al.¹⁹¹ used this technique and organoid integration to mimic perfused vessels for investigating the progression and response of cell lines and PDOs to chemotherapy and anti-angiogenic therapy. Many aspects remain to be improved in order to obtain more accurate and reliable results. Skilled and experienced researchers are required for the fabrication of microfluidic devices and sophisticated tissue engineering techniques. Another potential limitation is that biomaterials used to fabricate many organ chips cannot be effectively used for drug research due to drug absorption.

Optical metabolic imaging (OMI) measures drug-induced changes in cellular metabolism and may shorten drug turnover times and be used to test drug responses in individualized cancer treatment.^{192,193} The susceptibility of gastroenteropancreatic neuroendocrine tumor (GEP-NET)

organoids to navitoclax (Bcl-2 inhibitor) and everolimus (mTOR inhibitor GEP-NET treatment) has been evaluated by OMI.¹⁹⁴ 3D bioprinting allows precise control of spatial heterogeneity in the tumor microenvironment through spatially deterministic deposition of predefined biobanks that may contain multiple cell types, biochemical factors, and ECM. Reid et al generated chimeric organoids by co-printing cancer cells and normal breast epithelial cells and showed that cancer cells within the chimeric construct had significantly increased levels of 5-hydroxymethylcytosine compared to bio-printed tumor-like cells.¹⁹⁵ In addition, organoid technology, microfluidic technology, and 3D printing technology have been combined into an automated organoid platform for one-week high-throughput drug screening and personalized medicines.¹⁹⁶ When limitations are eventually overcome, organoids may give new hope to cancer patients and greatly promote human health.

Conclusions

Patient-derived tumor organoids are physiologically and clinically more advanced and maintain patient-specific tumor heterogeneity, constituting a good platform for different tumors. This model allows the simulation of tumor development to provide new targets for cancer therapy and facilitate appropriate treatment selection. Some complex cancer organoids may become tools for personalized immunotherapy validation, response and toxicity testing, and therapeutic development in early clinical trials. Therefore, tumor-derived organoids are an important tool through which we can improve the understanding of cancer and promote the treatment of cancer patients in the future.

Author contributions

XM and QW collected the related paper and drafted the manuscript. GL and HL revised the manuscript and prepared the figures. DP and SX participated in the design of the review and helped draft and modify the manuscript. All authors read and approved the final manuscript.

Conflict of interests

The authors declared that there is no conflict of interests.

Funding

This work was supported by grants from the Project Nn10 of Harbin Medical University Cancer Hospital, Heilongjiang, China (No. Nn102017-02), the National Natural Science Foundation of China (No. 81972706, 81872149, 82173235, 82072904, 82103325), Outstanding Youth Project of Heilongjiang Provincial Natural Science Foundation, Heilongjiang, China (No. YQ2019H027), Distinguished Young Scholars of Harbin Medical University Cancer Hospital, Heilongjiang, China (No. JCQN2018-03), Yong Elite Training Foundation Grant of Harbin Medical University Cancer Hospital, Heilongjiang, China (No. JY2016-02), and Haiyan Fund Project of Harbin Medical University Cancer Hospital, Heilongjiang, China (No. JJMS 2022–17).

Acknowledgements

The authors would like to express their gratitude to Edit-Springs (<https://www.editsprings.cn>) for the expert linguistic services provided.

References

- Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA A Cancer J Clin*. 2021;71(3):209–249.
- Kapaczynska M, Kolenda T, Przybyla W, et al. 2D and 3D cell cultures – a comparison of different types of cancer cell cultures. *Arch Med Sci*. 2018;14(4):910–919.
- Sato T, Vries RG, Snippert HJ, et al. Single Lgr5 stem cells build crypt-villus structures *in vitro* without a mesenchymal niche. *Nature*. 2009;459(7244):262–265.
- Lancaster MA, Knoblich JA. Organogenesis in a dish: modeling development and disease using organoid technologies. *Science*. 2014;345(6194):1247125.
- Tuveson D, Clevers H. Cancer modeling meets human organoid technology. *Science*. 2019;364(6444):952–955.
- Qu J, Kalyani FS, Liu L, et al. Tumor organoids: synergistic applications, current challenges, and future prospects in cancer therapy. *Cancer Commun*. 2021;41(12):1331–1353.
- Yang H, Wang Y, Wang P, et al. Tumor organoids for cancer research and personalized medicine. *Cancer Biol Med*. 2021;19(3):319–332.
- Sato T, Stange DE, Ferrante M, et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. *Gastroenterology*. 2011;141(5):1762–1772.
- Pringle S, Maimets M, van der Zwaag M, et al. Human salivary gland stem cells functionally restore radiation damaged salivary glands. *Stem Cell*. 2016;34(3):640–652.
- Li X, Nadauld L, Ootani A, et al. Oncogenic transformation of diverse gastrointestinal tissues in primary organoid culture. *Nat Med*. 2014;20(7):769–777.
- Fan H, Demirci U, Chen P. Emerging organoid models: leaping forward in cancer research. *J Hematol Oncol*. 2019;12:142.
- Driehuis E, Kretschmar K, Clevers H. Establishment of patient-derived cancer organoids for drug-screening applications. *Nat Protoc*. 2020;15(10):3380–3409.
- Gao D, Vela I, Sboner A, et al. Organoid cultures derived from patients with advanced prostate cancer. *Cell*. 2014;159(1):176–187.
- Sachs N, de Ligt J, Kopper O, et al. A living biobank of breast cancer organoids captures disease heterogeneity. *Cell*. 2018;172(1–2):373–386.
- Dekkers JF, van Vliet EJ, Sachs N, et al. Long-term culture, genetic manipulation and xenotransplantation of human normal and breast cancer organoids. *Nat Protoc*. 2021;16(4):1936–1965.
- Mullenders J, de Jongh E, Brousalı A, et al. Mouse and human urothelial cancer organoids: a tool for bladder cancer research. *Proc Natl Acad Sci U S A*. 2019;116(10):4567–4574.
- Van de Wetering M, Francies H, Francis J, et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. *Cell*. 2015;161(4):933–945.
- Fujii M, Shimokawa M, Date S, et al. A colorectal tumor organoid library demonstrates progressive loss of niche factor requirements during tumorigenesis. *Cell Stem Cell*. 2016;18(6):827–838.
- Francies HE, Barthorpe A, McLaren-Douglas A, et al. Drug sensitivity assays of human cancer organoid cultures. *Methods Mol Biol*. 2019;1576:339–351.
- Bartfeld S, Bayram T, van de Wetering M, et al. *In vitro* expansion of human gastric epithelial stem cells and their responses to bacterial infection. *Gastroenterology*. 2015;148(1):126–136.
- Wang Z, Guo Y, Jin Y, et al. Establishment and drug screening of patient-derived extrahepatic biliary tract carcinoma organoids. *Cancer Cell Int*. 2021;21:519.
- Yuan B, Zhao X, Wang X, et al. Patient-derived organoids for personalized gallbladder cancer modelling and drug screening. *Clin Transl Med*. 2022;12(1):e678.
- Hubert CG, Rivera M, Spangler LC, et al. A three-dimensional organoid culture system derived from human glioblastomas recapitulates the hypoxic gradients and cancer stem cell heterogeneity of tumors found *in vivo*. *Cancer Res*. 2016;76(8):2465–2477.
- Jacob F, Salinas RD, Zhang DY, et al. A patient-derived glioblastoma organoid model and biobank recapitulates inter- and intra-tumoral heterogeneity. *Cell*. 2020;180(1):188–204.
- Driehuis E, Kolders S, Spelier S, et al. Oral mucosal organoids as a potential platform for personalized cancer therapy. *Cancer Discov*. 2019;9(7):852–871.
- Schutgens F, Rookmaaker MB, Margaritis T, et al. Tubuloids derived from human adult kidney and urine for personalized disease modeling. *Nat Biotechnol*. 2019;37(3):303–313.
- Calandrini C, Schutgens F, Oka R, et al. An organoid biobank for childhood kidney cancers that captures disease and tissue heterogeneity. *Nat Commun*. 2020;11:1310.
- Huch M, Gehart H, van Boxtel R, et al. Long-term culture of genome-stable bipotent stem cells from adult human liver. *Cell*. 2015;160(1–2):299–312.
- Broutier L, Mastrogiorganni G, Verstegen MM, et al. Human primary liver cancer-derived organoid cultures for disease modeling and drug screening. *Nat Med*. 2017;23(12):1424–1435.
- Kim M, Mun H, Sung CO, et al. Patient-derived lung cancer organoids as *in vitro* cancer models for therapeutic screening. *Nat Commun*. 2019;10:3991.
- Shi R, Radulovich N, Ng C, et al. Organoid cultures as pre-clinical models of non-small cell lung cancer. *Clin Cancer Res*. 2020;26(5):1162–1174.
- Kopper O, de Witte CJ, Löhmusaar K, et al. An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity. *Nat Med*. 2019;25(5):838–849.
- Hill SJ, Decker B, Roberts EA, et al. Prediction of DNA repair inhibitor response in short-term patient-derived ovarian cancer organoids. *Cancer Discov*. 2018;8(11):1404–1421.
- Boj SF, Hwang CI, Baker LA, et al. Organoid models of human and mouse ductal pancreatic cancer. *Cell*. 2015;160(1–2):324–338.
- Huang L, Holtzinger A, Jagan I, et al. Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids. *Nat Med*. 2015;21(11):1364–1371.
- Karkampouna S, La Manna F, Benjak A, et al. Patient-derived xenografts and organoids model therapy response in prostate cancer. *Nat Commun*. 2021;12:1117.
- Weeber F, van de Wetering M, Hoogstraat M, et al. Preserved genetic diversity in organoids cultured from biopsies of human colorectal cancer metastases. *Proc Natl Acad Sci U S A*. 2015;112(43):13308–13311.
- Sachs N, Clevers H. Organoid cultures for the analysis of cancer phenotypes. *Curr Opin Genet Dev*. 2014;24:68–73.
- Bhatia S, Kramer M, Russo S, et al. Patient-derived triple-negative breast cancer organoids provide robust model systems that recapitulate tumor intrinsic characteristics. *Cancer Res*. 2022;82(7):1174–1192.

40. Luo X, She J, Xu T, et al. Establishment and characterization of organoids from a patient with adenomyoepithelioma of the breast. *Bioengineered*. 2021;12(2):11578–11585.
41. Li X, Pan B, Song X, et al. Breast cancer organoids from a patient with giant papillary carcinoma as a high-fidelity model. *Cancer Cell Int*. 2020;20:86.
42. Pan B, Zhao D, Liu Y, et al. Establishment and characterization of breast cancer organoids from a patient with mammary Paget's disease. *Cancer Cell Int*. 2020;20:365.
43. Pan B, Zhao D, Liu Y, et al. Breast cancer organoids from malignant pleural effusion-derived tumor cells as an individualized medicine platform. *In Vitro Cell Dev Biol Anim*. 2021;57(5):510–518.
44. Dekkers JF, Whittle JR, Vaillant F, et al. Modeling breast cancer using CRISPR-Cas9-mediated engineering of human breast organoids. *J Natl Cancer Inst*. 2020;112(5):540–544.
45. Chen P, Zhang X, Ding R, et al. Patient-derived organoids can guide personalized-therapies for patients with advanced breast cancer. *Adv Sci*. 2021;8(22):e2101176.
46. Pan B, Li X, Zhao D, et al. Optimizing individualized treatment strategy based on breast cancer organoid model. *Clin Transl Med*. 2021;11(4):e380.
47. Zhao N, Powell RT, Yuan X, et al. Morphological screening of mesenchymal mammary tumor organoids to identify drugs that reverse epithelial-mesenchymal transition. *Nat Commun*. 2021;12:4262.
48. Carter ME, Hartkopf AD, Wagner A, et al. A three-dimensional organoid model of primary breast cancer to investigate the effects of oncolytic virotherapy. *Front Mol Biosci*. 2022;9:826302.
49. Cai EY, Garcia J, Liu Y, et al. A bladder cancer patient-derived xenograft displays aggressive growth dynamics *in vivo* and in organoid culture. *Sci Rep*. 2021;11:4609.
50. Gong Z, Huang L, Tang X, et al. Acoustic droplet printing tumor organoids for modeling bladder tumor immune micro-environment within a week. *Adv Healthc Mater*. 2021;10(22):e2101312.
51. Kong J, Lee H, Kim D, et al. Network-based machine learning in colorectal and bladder organoid models predicts anti-cancer drug efficacy in patients. *Nat Commun*. 2020;11:5485.
52. Yu L, Li Z, Mei H, et al. Patient-derived organoids of bladder cancer recapitulate antigen expression profiles and serve as a personal evaluation model for CAR-T cells *in vitro*. *Clin Transl Immunology*. 2021;10(2):e1248.
53. Yan HHN, Siu HC, Ho SL, et al. Organoid cultures of early-onset colorectal cancers reveal distinct and rare genetic profiles. *Gut*. 2020;69(12):2165–2179.
54. Li H, Dai W, Xia X, et al. Modeling tumor development and metastasis using paired organoids derived from patients with colorectal cancer liver metastases. *J Hematol Oncol*. 2020;13:119.
55. Zhao H, Yan C, Hu Y, et al. Differentiated cancer cell-originated lactate promotes the self-renewal of cancer stem cells in patient-derived colorectal cancer organoids. *Cancer Lett*. 2020;493:236–244.
56. Costales-Carrera A, Fernández-Barral A, Bustamante-Madrid P, et al. Comparative study of organoids from patient-derived normal and tumor colon and rectal tissue. *Cancers*. 2020;12(8):2302.
57. Hu X, Zhang L, Li Y, et al. Organoid modelling identifies that DACH1 functions as a tumour promoter in colorectal cancer by modulating BMP signalling. *EBioMedicine*. 2020;56:102800.
58. Post JB, Roodhart JML, Snippert HJG. Colorectal cancer modeling with organoids: discriminating between oncogenic RAS and BRAF variants. *Trends Cancer*. 2020;6(2):111–129.
59. Bruun J, Kryeziu K, Eide PW, et al. Patient-derived organoids from multiple colorectal cancer liver metastases reveal moderate intra-patient pharmacotranscriptomic heterogeneity. *Clin Cancer Res*. 2020;26(15):4107–4119.
60. Nagai H, Kuroha M, Handa T, et al. Comprehensive analysis of microRNA profiles in organoids derived from human colorectal adenoma and cancer. *Digestion*. 2021;102(6):860–869.
61. Luo X, Fong ELS, Zhu C, et al. Hydrogel-based colorectal cancer organoid co-culture models. *Acta Biomater*. 2021;132:461–472.
62. Cho YW, Min DW, Kim HP, et al. Patient-derived organoids as a preclinical platform for precision medicine in colorectal cancer. *Mol Oncol*. 2022;16(12):2396–2412.
63. Li Q, Sun H, Luo D, et al. Lnc-RP11-536 K_{7,3}/SOX2/HIF-1 α signaling axis regulates oxaliplatin resistance in patient-derived colorectal cancer organoids. *J Exp Clin Cancer Res*. 2021;40:348.
64. Yao Y, Xu X, Yang L, et al. Patient-derived organoids predict chemoradiation responses of locally advanced rectal cancer. *Cell Stem Cell*. 2020;26(1):17–26.e6.
65. Engel RM, Chan WH, Nickless D, et al. Patient-derived colorectal cancer organoids upregulate revival stem cell marker genes following chemotherapeutic treatment. *J Clin Med*. 2020;9(1):128.
66. Ooft SN, Weeber F, Schipper L, et al. Prospective experimental treatment of colorectal cancer patients based on organoid drug responses. *ESMO Open*. 2021;6(3):100103.
67. Jung YH, Choi DH, Park K, et al. Drug screening by uniform patient derived colorectal cancer hydro-organoids. *Bio-materials*. 2021;276:121004.
68. Norkin M, Ordóñez-Morán P, Huelsken J. High-content, targeted RNA-seq screening in organoids for drug discovery in colorectal cancer. *Cell Rep*. 2021;35(3):109026.
69. Ukai S, Honma R, Sakamoto N, et al. Molecular biological analysis of 5-FU-resistant gastric cancer organoids; KHDRBS3 contributes to the attainment of features of cancer stem cell. *Oncogene*. 2020;39(50):7265–7278.
70. Harada K, Sakamoto N, Ukai S, et al. Establishment of oxaliplatin-resistant gastric cancer organoids: importance of myoferlin in the acquisition of oxaliplatin resistance. *Gastric Cancer*. 2021;24(6):1264–1277.
71. Koh V, Chakrabarti J, Torvund M, et al. Hedgehog transcriptional effector GLI mediates mTOR-Induced PD-L1 expression in gastric cancer organoids. *Cancer Lett*. 2021;518:59–71.
72. Chakrabarti J, Koh V, Steele N, et al. Disruption of Her2-induced PD-L1 inhibits tumor cell immune evasion in patient-derived gastric cancer organoids. *Cancers*. 2021;13(24):6158.
73. Lo YH, Kolahi KS, Du Y, et al. A CRISPR/Cas9-engineered ARID1A-deficient human gastric cancer organoid model reveals essential and nonessential modes of oncogenic transformation. *Cancer Discov*. 2021;11(6):1562–1581.
74. Li H, Wang C, Lan L, et al. PARP1 inhibitor combined with oxaliplatin efficiently suppresses oxaliplatin resistance in gastric cancer-derived organoids via homologous recombination and the base excision repair pathway. *Front Cell Dev Biol*. 2021;9:719192.
75. Ku CC, Wuputra K, Pan JB, et al. Generation of human stomach cancer iPSC-derived organoids induced by *Helicobacter pylori* infection and their application to gastric cancer research. *Cells*. 2022;11(2):184.
76. Li G, Ma S, Wu Q, et al. Establishment of gastric signet ring cell carcinoma organoid for the therapeutic drug testing. *Cell Death Dis*. 2022;8:6.
77. Wang S, Wang Y, Xun X, et al. Hedgehog signaling promotes sorafenib resistance in hepatocellular carcinoma patient-derived organoids. *J Exp Clin Cancer Res*. 2020;39:22.
78. Liu J, Li P, Wang L, et al. Cancer-associated fibroblasts provide a stromal niche for liver cancer organoids that confers trophic effects and therapy resistance. *Cell Mol Gastroenterol Hepatol*. 2021;11(2):407–431.

79. Dost AFM, Moye AL, Vedaie M, et al. Organoids model transcriptional hallmarks of oncogenic KRAS activation in lung epithelial progenitor cells. *Cell Stem Cell*. 2020;27(4):663–678.
80. Kim SY, Kim SM, Lim S, et al. Modeling clinical responses to targeted therapies by patient-derived organoids of advanced lung adenocarcinoma. *Clin Cancer Res*. 2021;27(15):4397–4409.
81. Ma X, Yang S, Jiang H, et al. Transcriptomic analysis of tumor tissues and organoids reveals the crucial genes regulating the proliferation of lung adenocarcinoma. *J Transl Med*. 2021;19:368.
82. Miura A, Yamada D, Nakamura M, et al. Oncogenic potential of human pluripotent stem cell-derived lung organoids with HER2 overexpression. *Int J Cancer*. 2021;149(8):1593–1604.
83. Choi SY, Cho YH, Kim DS, et al. Establishment and long-term expansion of small cell lung cancer patient-derived tumor organoids. *Int J Mol Sci*. 2021;22(3):1349.
84. Lu T, Cao Y, Zhao P, et al. Organoid: a powerful tool to study lung regeneration and disease. *Cell Regen*. 2021;10:21.
85. Dijkstra KK, Monkhorst K, Schipper LJ, et al. Challenges in establishing pure lung cancer organoids limit their utility for personalized medicine. *Cell Rep*. 2020;31(5):107588.
86. Gmeiner WH, Miller LD, Chou JW, et al. Dysregulated pyrimidine biosynthesis contributes to 5-FU resistance in SCLC patient-derived organoids but response to a novel polymeric fluoropyrimidine, CF10. *Cancers*. 2020;12(4):788.
87. Chen JH, Chu XP, Zhang JT, et al. Genomic characteristics and drug screening among organoids derived from non-small cell lung cancer patients. *Thorac Cancer*. 2020;11(8):2279–2290.
88. Hoffmann K, Berger H, Kulbe H, et al. Stable expansion of high-grade serous ovarian cancer organoids requires a low-Wnt environment. *EMBO J*. 2020;39(6):e104013.
89. Chen H, Gotimer K, De Souza C, et al. Short-term organoid culture for drug sensitivity testing of high-grade serous carcinoma. *Gynecol Oncol*. 2020;157(3):783–792.
90. Nanki Y, Chiyoda T, Hirasawa A, et al. Patient-derived ovarian cancer organoids capture the genomic profiles of primary tumours applicable for drug sensitivity and resistance testing. *Sci Rep*. 2020;10:12581.
91. de Witte CJ, Espejo Valle-Inclan J, Hami N, et al. Patient-derived ovarian cancer organoids mimic clinical response and exhibit heterogeneous inter- and inpatient drug responses. *Cell Rep*. 2020;31(11):107762.
92. Bi J, Newton AM, Zhang Y, et al. Successful patient-derived organoid culture of gynecologic cancers for disease modeling and drug sensitivity testing. *Cancers*. 2021;13(12):2901.
93. Zhang S, Iyer S, Ran H, et al. Genetically defined, syngeneic organoid platform for developing combination therapies for ovarian cancer. *Cancer Discov*. 2021;11(2):362–383.
94. Gorski JW, Zhang Z, McCorkle JR, et al. Utilizing patient-derived epithelial ovarian cancer tumor organoids to predict carboplatin resistance. *Biomedicines*. 2021;9(8):1021.
95. Nelson SR, Zhang C, Roche S, et al. Modelling of pancreatic cancer biology: transcriptomic signature for 3D PDX-derived organoids and primary cell line organoid development. *Sci Rep*. 2020;10:2778.
96. Huang W, Navarro-Serer B, Jeong YJ, et al. Pattern of invasion in human pancreatic cancer organoids is associated with loss of SMAD4 and clinical outcome. *Cancer Res*. 2020;80(13):2804–2817.
97. Holokai L, Chakrabarti J, Lundy J, et al. Murine- and human-derived autologous organoid/immune cell Co-cultures as pre-clinical models of pancreatic ductal adenocarcinoma. *Cancers*. 2020;12(12):3816.
98. Matsuura T, Maru Y, Izumiya M, et al. Organoid-based *ex vivo* reconstitution of Kras-driven pancreatic ductal carcinogenesis. *Carcinogenesis*. 2020;41(4):490–501.
99. Braun LM, Lagies S, Klar RFU, et al. Metabolic profiling of early and late recurrent pancreatic ductal adenocarcinoma using patient-derived organoid cultures. *Cancers*. 2020;12(6):1440.
100. Choi JI, Jang SI, Hong J, et al. Cancer-initiating cells in human pancreatic cancer organoids are maintained by interactions with endothelial cells. *Cancer Lett*. 2021;498:42–53.
101. Lacomb JF, Plenker D, Tiriack H, et al. Single-pass vs 2-pass endoscopic ultrasound-guided fine-needle biopsy sample collection for creation of pancreatic adenocarcinoma organoids. *Clin Gastroenterol Hepatol*. 2021;19(4):845–847.
102. Raimondi G, Mato-Berciano A, Pascual-Sabater S, et al. Patient-derived pancreatic tumour organoids identify therapeutic responses to oncolytic adenoviruses. *EBioMedicine*. 2020;56:102786.
103. Palzer J, Mues B, Goerg R, et al. Magnetic fluid hyperthermia as treatment option for pancreatic cancer cells and pancreatic cancer organoids. *Int J Nanomed*. 2021;16:2965–2981.
104. Huang B, Trujillo MA, Fujikura K, et al. Molecular characterization of organoids derived from pancreatic intraductal papillary mucinous neoplasms. *J Pathol*. 2020;252(3):252–262.
105. Beato F, Reverón D, Dezsí KB, et al. Establishing a living biobank of patient-derived organoids of intraductal papillary mucinous neoplasms of the pancreas. *Lab Invest*. 2021;101(2):204–217.
106. Dantes Z, Yen HY, Pfarr N, et al. Implementing cell-free DNA of pancreatic cancer patient-derived organoids for personalized oncology. *JCI Insight*. 2020;5(15):e137809.
107. Servant R, Garioni M, Vlainic T, et al. Prostate cancer patient-derived organoids: detailed outcome from a prospective cohort of 81 clinical specimens. *J Pathol*. 2021;254(5):543–555.
108. Heninger E, Kosoff D, Rodems TS, et al. Live cell molecular analysis of primary prostate cancer organoids identifies persistent androgen receptor signaling. *Med Oncol*. 2021;38(11):135.
109. Choo N, Ramm S, Luu J, et al. High-throughput imaging assay for drug screening of 3D prostate cancer organoids. *SLAS Discov*. 2021;26(9):1107–1124.
110. Kijima T, Nakagawa H, Shimonosono M, et al. Three-dimensional organoids reveal therapy resistance of esophageal and oropharyngeal squamous cell carcinoma cells. *Cell Mol Gastroenterol Hepatol*. 2019;7(1):73–91.
111. Derouet MF, Allen J, Wilson GW, et al. Towards personalized induction therapy for esophageal adenocarcinoma: organoids derived from endoscopic biopsy recapitulate the pre-treatment tumor. *Sci Rep*. 2020;10:14514.
112. Karakasheva TA, Gabre JT, Sachdeva UM, et al. Patient-derived organoids as a platform for modeling a patient's response to chemoradiotherapy in esophageal cancer. *Sci Rep*. 2021;11:21304.
113. Driehuis E, Spelier S, Beltrán Hernández I, et al. Patient-derived head and neck cancer organoids recapitulate EGFR expression levels of respective tissues and are responsive to EGFR-targeted photodynamic therapy. *J Clin Med*. 2019;8(11):1880.
114. Krieger TG, Tirier SM, Park J, et al. Modeling glioblastoma invasion using human brain organoids and single-cell transcriptomics. *Neuro Oncol*. 2020;22(8):1138–1149.
115. Jacob F, Ming GL, Song H. Generation and biobanking of patient-derived glioblastoma organoids and their application in CAR T cell testing. *Nat Protoc*. 2020;15(12):4000–4033.
116. Darrigues E, Zhao EH, De Loose A, et al. Biobanked glioblastoma patient-derived organoids as a precision medicine model to study inhibition of invasion. *Int J Mol Sci*. 2021;22(19):10720.
117. Golebiewska A, Hau AC, Oudin A, et al. Patient-derived organoids and orthotopic xenografts of primary and recurrent

- gliomas represent relevant patient avatars for precision oncology. *Acta Neuropathol.* 2020;140(6):919–949.
118. Pon JR, Marra MA. Driver and passenger mutations in cancer. *Annu Rev Pathol.* 2015;10:25–50.
 119. Helleday T, Eshtad S, Nik-Zainal S. Mechanisms underlying mutational signatures in human cancers. *Nat Rev Genet.* 2014;15(9):585–598.
 120. Guernet A, Grumolato L. CRISPR/Cas9 editing of the genome for cancer modeling. *Methods.* 2017;121–122:130–137.
 121. Drost J, van Jaarsveld RH, Ponsioen B, et al. Sequential cancer mutations in cultured human intestinal stem cells. *Nature.* 2015;521(7550):43–47.
 122. Matano M, Date S, Shimokawa M, et al. Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids. *Nat Med.* 2015;21(3):256–262.
 123. Naruse M, Masui R, Ochiai M, et al. An organoid-based carcinogenesis model induced by *in vitro* chemical treatment. *Carcinogenesis.* 2020;41(10):1444–1453.
 124. Han H, Davidson LA, Fan YY, et al. Loss of aryl hydrocarbon receptor suppresses the response of colonic epithelial cells to IL22 signaling by upregulating SOCS3. *Am J Physiol Gastrointest Liver Physiol.* 2022;322(1):G93–G106.
 125. Artegiani B, Hendriks D, Beumer J, et al. Fast and efficient generation of knock-in human organoids using homology-independent CRISPR-Cas9 precision genome editing. *Nat Cell Biol.* 2020;22(3):321–331.
 126. Hendriks D, Artegiani B, Hu H, et al. Establishment of human fetal hepatocyte organoids and CRISPR-Cas9-based gene knockin and knockout in organoid cultures from human liver. *Nat Protoc.* 2021;16(1):182–217.
 127. Steeg PS. Targeting metastasis. *Nat Rev Cancer.* 2016;16(4):201–218.
 128. Roukens MG, Frederiks CL, Seinstra D, et al. Regulation of a progenitor gene program by SOX4 is essential for mammary tumor proliferation. *Oncogene.* 2021;40(45):6343–6353.
 129. Hay M, Thomas DW, Craighead JL, et al. Clinical development success rates for investigational drugs. *Nat Biotechnol.* 2014;32(1):40–51.
 130. Voskoglou-Nomikos T, Pater JL, Seymour L. Clinical predictive value of the *in vitro* cell line, human xenograft, and mouse allograft preclinical cancer models. *Clin Cancer Res.* 2003;9(11):4227–4239.
 131. Vlachogiannis N, Hedayat S, Vatsiou A, et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. *Science.* 2018;359(6378):920–926.
 132. Saito Y, Muramatsu T, Kanai Y, et al. Establishment of patient-derived organoids and drug screening for biliary tract carcinoma. *Cell Rep.* 2019;27(4):1265–1276.
 133. Boos SL, Loevenich LP, Vosberg S, et al. Disease modeling on tumor organoids implicates AURKA as a therapeutic target in liver metastatic colorectal cancer. *Cell Mol Gastroenterol Hepatol.* 2022;13(2):517–540.
 134. Sánchez-Botet A, Quandt E, Masip N, et al. Atypical cyclin P regulates cancer cell stemness through activation of the WNT pathway. *Cell Oncol.* 2021;44(6):1273–1286.
 135. Verissimo CS, Overmeer RM, Ponsioen B, et al. Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening. *Elife.* 2016;5:e18489.
 136. Wang T, Pan W, Zheng H, et al. Accuracy of using a patient-derived tumor organoid culture model to predict the response to chemotherapy regimens in stage IV colorectal cancer: a blinded study. *Dis Colon Rectum.* 2021;64(7):833–850.
 137. Costales-Carrera A, Fernández-Barral A, Bustamante-Madrid P, et al. Plocabulin displays strong cytotoxic activity in a personalized colon cancer patient-derived 3D organoid assay. *Mar Drugs.* 2019;17(11):648.
 138. Katsuda T, Kawamata M, Hagiwara K, et al. Conversion of terminally committed hepatocytes to culturable bipotent progenitor cells with regenerative capacity. *Cell Stem Cell.* 2017;20(1):41–55.
 139. Mekky G, Seeds M, Diab AEA, et al. The potential toxic effects of magnesium oxide nanoparticles and valproate on liver tissue. *J Biochem Mol Toxicol.* 2021;35(3):e22676.
 140. Shinozawa T, Kimura M, Cai Y, et al. High-fidelity drug-induced liver injury screen using human pluripotent stem cell-derived organoids. *Gastroenterology.* 2021;160(3):831–846.
 141. Richards DJ, Li Y, Kerr CM, et al. Human cardiac organoids for the modelling of myocardial infarction and drug cardiotoxicity. *Nat Biomed Eng.* 2020;4(4):446–462.
 142. Lee J, Sutani A, Kaneko R, et al. *In vitro* generation of functional murine heart organoids via FGF₄ and extracellular matrix. *Nat Commun.* 2020;11:4283.
 143. Lee SJ, Kim HA, Kim SJ, et al. Improving generation of cardiac organoids from human pluripotent stem cells using the aurora kinase inhibitor ZM447439. *Biomedicines.* 2021;9(12):1952.
 144. Freedman BS, Brooks CR, Lam AQ, et al. Modelling kidney disease with CRISPR-mutant kidney organoids derived from human pluripotent epiblast spheroids. *Nat Commun.* 2015;6:8715.
 145. Galluzzi L, Vacchelli E, Pedro JMBS, et al. Classification of current anticancer immunotherapies. *Oncotarget.* 2014;5(24):12472–12508.
 146. Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. *Nat Rev Immunol.* 2020;20(11):651–668.
 147. Palucka A, Coussens L. The basis of oncoimmunology. *Cell.* 2016;164(6):1233–1247.
 148. Christofi T, Baritaki S, Falzone L, et al. Current perspectives in cancer immunotherapy. *Cancers.* 2019;11(10):1472.
 149. Dijkstra KK, Cattaneo CM, Weeber F, et al. Generation of tumor-reactive T cells by Co-culture of peripheral blood lymphocytes and tumor organoids. *Cell.* 2018;174(6):1586–1598.
 150. Jenkins RW, Aref AR, Lizotte PH, et al. *Ex vivo* profiling of PD-1 blockade using organotypic tumor spheroids. *Cancer Discov.* 2018;8(2):196–215.
 151. Neal JT, Li X, Zhu J, et al. Organoid modeling of the tumor immune microenvironment. *Cell.* 2018;175(7):1972–1988.
 152. Chen J, Sun HW, Yang YY, et al. Reprogramming immunosuppressive myeloid cells by activated T cells promotes the response to anti-PD-1 therapy in colorectal cancer. *Signal Transduct Target Ther.* 2021;6(1):4.
 153. Wörsdörfer P, Dalda N, Kern A, et al. Generation of complex human organoid models including vascular networks by incorporation of mesodermal progenitor cells. *Sci Rep.* 2019;9(1):15663.
 154. Grebenyuk S, Ranga A. Engineering organoid vascularization. *Front Bioeng Biotechnol.* 2019;7:39.
 155. Nashimoto Y, Hayashi T, Kunita I, et al. Integrating perfusable vascular networks with a three-dimensional tissue in a microfluidic device. *Integr Biol.* 2017;9(6):506–518.
 156. Rodewald HR. Thymus organogenesis. *Annu Rev Immunol.* 2008;26:355–388.
 157. Farley AM, Morris LX, Vroegindeweij E, et al. Dynamics of thymus organogenesis and colonization in early human development. *Development.* 2013;140(9):2015–2026.
 158. Robin C, Bennaceur-Griscelli A, Louache F, et al. Identification of human T-lymphoid progenitor cells in CD34⁺ CD38^{low} and CD34⁺ CD38⁺ subsets of human cord blood and bone marrow cells using NOD-SCID fetal thymus organ cultures. *Br J Haematol.* 1999;104(4):809–819.

159. Deng Z, Liu H, Rui J, et al. Reconstituted *Thymus* organ culture. *Methods Mol Biol.* 2016;1323:151–158.
160. Selvaratnam JS, T SH, Anderson MK. Fetal thymic organ culture (FTOC) optimized for gamma-delta T cell studies. *Methods Mol Biol.* 2022;2421:243–265.
161. Sharma H, Moroni L. Recent advancements in regenerative approaches for *Thymus* rejuvenation. *Adv Sci.* 2021;8(14):2100543.
162. Seet CS, He C, Bethune MT, et al. Generation of mature T cells from human hematopoietic stem and progenitor cells in artificial thymic organoids. *Nat Methods.* 2017;14(5):521–530.
163. Gardner CL, Pavel-Dinu M, Dobbs K, et al. Gene editing rescues *in vitro* T cell development of RAG2-deficient induced pluripotent stem cells in an artificial thymic organoid system. *J Clin Immunol.* 2021;41(5):852–862.
164. Bosticardo M, Pala F, Calzoni E, et al. Artificial thymic organoids represent a reliable tool to study T-cell differentiation in patients with severe T-cell lymphopenia. *Blood Adv.* 2020;4(12):2611–2616. *Blood Adv.* 2020;4(15):3507.
165. Gasteiger G, Ataide M, Kastenmüller W. Lymph node - an organ for T-cell activation and pathogen defense. *Immunol Rev.* 2016;271(1):200–220.
166. Suematsu S, Watanabe T. Generation of a synthetic lymphoid tissue-like organoid in mice. *Nat Biotechnol.* 2004;22(12):1539–1545.
167. Votanopoulos KI, Forsythe S, Sivakumar H, et al. Model of patient-specific immune-enhanced organoids for immunotherapy screening: feasibility study. *Ann Surg Oncol.* 2020;27(6):1956–1967.
168. Xia X, Zhou W, Guo C, et al. Glutaminolysis mediated by MALT1 protease activity facilitates PD-L1 expression on ABC-DLBCL cells and contributes to their immune evasion. *Front Oncol.* 2018;8:632.
169. Lenz G, Davis RE, Ngo VN, et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. *Science.* 2008;319(5870):1676–1679.
170. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. *N Engl J Med.* 2019;381(16):1535–1546.
171. Migden MR, Rischin D, Schmults CD, et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. *N Engl J Med.* 2018;379(4):341–351.
172. Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. *N Engl J Med.* 2018;378(24):2288–2301.
173. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. *N Engl J Med.* 2015;373(19):1803–1813.
174. Bins S, van Meerten E, Mathijssen RH. Nivolumab for squamous-cell cancer of head and neck. *N Engl J Med.* 2017;376(6):595–596.
175. Syn NL, Teng MWL, Mok TSK, et al. De-novo and acquired resistance to immune checkpoint targeting. *Lancet Oncol.* 2017;18(12):e731–e741.
176. Kong JCH, Guerra GR, Millen RM, et al. Tumor-infiltrating lymphocyte function predicts response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. *JCO Precis Oncol.* 2018;2:1–15.
177. Courau T, Bonnereau J, Chicoteau J, et al. Cocultures of human colorectal tumor spheroids with immune cells reveal the therapeutic potential of MICA/B and NKG2A targeting for cancer treatment. *J Immunother Cancer.* 2019;7:74.
178. Deng J, Wang ES, Jenkins RW, et al. CDK4/6 inhibition augments antitumor immunity by enhancing T-cell activation. *Cancer Discov.* 2018;8(2):216–233.
179. Esser LK, Branchi V, Leonardelli S, et al. Cultivation of clear cell renal cell carcinoma patient-derived organoids in an air-liquid interface system as a tool for studying individualized therapy. *Front Oncol.* 2020;10:1775.
180. June CH, O'Connor RS, Kawalekar OU, et al. CAR T cell immunotherapy for human cancer. *Science.* 2018;359(6382):1361–1365.
181. Schnalzger TE, de Groot MH, Zhang C, et al. 3D model for CAR-mediated cytotoxicity using patient-derived colorectal cancer organoids. *EMBO J.* 2019;38(12):e100928.
182. Zou F, Tan J, Liu T, et al. The CD39⁺ HBV surface protein-targeted CAR-T and personalized tumor-reactive CD8⁺ T cells exhibit potent anti-HCC activity. *Mol Ther.* 2021;29(5):1794–1807.
183. Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. *Nat Rev Drug Discov.* 2016;15(9):660.
184. Zhu Z, Gorman MJ, McKenzie LD, et al. Zika virus has oncolytic activity against glioblastoma stem cells. *J Exp Med.* 2017;214(10):2843–2857.
185. Hamdan F, Ylösmäki E, Chiaro J, et al. Novel oncolytic adenovirus expressing enhanced cross-hybrid IgG A Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing *in vitro*, *in vivo* and with patient-derived tumor organoids. *J Immunother Cancer.* 2021;9(8):e003000.
186. Karthaus WR, Iaquinia PJ, Drost J, et al. Identification of multipotent luminal progenitor cells in human prostate organoid cultures. *Cell.* 2014;159(1):163–175.
187. Yin S, Xi R, Wu A, et al. Patient-derived tumor-like cell clusters for drug testing in cancer therapy. *Sci Transl Med.* 2020;12(549):eaaz1723.
188. Truong DD, Kratz A, Park JG, et al. A human organotypic microfluidic tumor model permits investigation of the interplay between patient-derived fibroblasts and breast cancer cells. *Cancer Res.* 2019;79(12):3139–3151.
189. Park SE, Georgescu A, Huh D. Organoids-on-a-chip. *Science.* 2019;364(6444):960–965.
190. Hu Y, Sui X, Song F, et al. Lung cancer organoids analyzed on microwell arrays predict drug responses of patients within a week. *Nat Commun.* 2021;12:2581.
191. Shirure VS, Bi Y, Curtis MB, et al. Tumor-on-a-chip platform to investigate progression and drug sensitivity in cell lines and patient-derived organoids. *Lab Chip.* 2018;18(23):3687–3702.
192. Walsh AJ, Castellanos JA, Nagathihalli NS, et al. Optical imaging of drug-induced metabolism changes in murine and human pancreatic cancer organoids reveals heterogeneous drug response. *Pancreas.* 2016;45(6):863–869.
193. Walsh AJ, Cook RS, Skala MC. Functional optical imaging of primary human tumor organoids: development of a personalized drug screen. *J Nucl Med.* 2017;58(9):1367–1372.
194. Gillette AA, Babiarz CP, VanDommelen AR, et al. Auto-fluorescence imaging of treatment response in neuroendocrine tumor organoids. *Cancers.* 2021;13(8):1873.
195. Reid JA, Palmer XL, Mollica PA, et al. A 3D bioprinter platform for mechanistic analysis of tumoroids and chimeric mammary organoids. *Sci Rep.* 2019;9:7466.
196. Jiang S, Zhao H, Zhang W, et al. An automated organoid platform with inter-organoid homogeneity and inter-patient heterogeneity. *Cell Rep Med.* 2020;1(9):100161.
197. Mazzucchelli S, Piccotti F, Allevi R, et al. Establishment and morphological characterization of patient-derived organoids from breast cancer. *Biol Proced Online.* 2019;21:12.
198. Lee SH, Hu W, Matulay JT, et al. Tumor evolution and drug response in patient-derived organoid models of bladder cancer. *Cell.* 2018;173(2):515–528.e17.

199. Yan HHN, Siu HC, Law S, et al. A comprehensive human gastric cancer organoid biobank captures tumor subtype heterogeneity and enables therapeutic screening. *Cell Stem Cell*. 2018;23(6):882–897.e11.
200. Li Y, Gao Y, Liang B, et al. Patient-derived organoids of non-small cells lung cancer and their application for drug screening. *Neoplasia*. 2020;67(2):430–437.
201. Nuciforo S, Fofana I, Matter MS, et al. Organoid models of human liver cancers derived from tumor needle biopsies. *Cell Rep*. 2018;24(5):1363–1376.
202. Tiriác H, Belleau P, Engle DD, et al. Organoid profiling identifies common responders to chemotherapy in pancreatic cancer. *Cancer Discov*. 2018;8(9):1112–1129.
203. Seino T, Kawasaki S, Shimokawa M, et al. Human pancreatic tumor organoids reveal loss of stem cell niche factor dependence during disease progression. *Cell Stem Cell*. 2018;22(3):454–467.e6.
204. Kawasaki K, Toshimitsu K, Matano M, et al. An Organoid Biobank of Neuroendocrine Neoplasms Enables Genotype-Phenotype Mapping. *Cell*. 2020;183(5):1420–1435.e21.